早期肿瘤药物研发中的药代动力学和药效学生物标志物 - Suppr

Suppr

超能文献

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.

作者信息

Takimoto Chris H

机构信息

Ortho Biotech Oncology Research & Development, Radnor, PA, USA.

出版信息

Eur J Cancer. 2009 Sep;45 Suppl 1:436-8. doi: 10.1016/S0959-8049(09)70080-2.

DOI:10.1016/S0959-8049(09)70080-2

PMID:19775662

Abstract

摘要

相似文献

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.

Eur J Cancer. 2009 Sep;45 Suppl 1:436-8. doi: 10.1016/S0959-8049(09)70080-2.

Using biomarkers in drug development.

Clin Adv Hematol Oncol. 2006 Oct;4(10):736-9.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. doi: 10.1158/1078-0432.CCR-03-0785.

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18.

Pharmacodynamic biomarkers for molecular cancer therapeutics.

Adv Cancer Res. 2007;96:213-68. doi: 10.1016/S0065-230X(06)96008-4.

Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086.

Biomarkers in early cancer drug development: limited utility.

Clin Pharmacol Ther. 2009 Feb;85(2):134-5. doi: 10.1038/clpt.2008.231.

Ex vivo biomarkers: functional tools to guide targeted drug development and therapy.

Expert Rev Mol Diagn. 2009 Nov;9(8):787-94. doi: 10.1586/erm.09.62.

Promises of biomarkers in drug development--a reality check.

Chem Biol Drug Des. 2007 Jun;69(6):381-94. doi: 10.1111/j.1747-0285.2007.00522.x.

New science-based endpoints to accelerate oncology drug development.

Eur J Cancer. 2005 Mar;41(4):491-501. doi: 10.1016/j.ejca.2004.12.006. Epub 2005 Jan 22.

引用本文的文献

NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA.

bioRxiv. 2024 Dec 25:2024.12.25.630315. doi: 10.1101/2024.12.25.630315.

Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Nat Rev Clin Oncol. 2021 Jul;18(7):454-467. doi: 10.1038/s41571-021-00489-x. Epub 2021 Mar 24.

Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.

Oncotarget. 2017 Jul 18;8(29):48178-48185. doi: 10.18632/oncotarget.18380.

Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

AAPS J. 2013 Apr;15(2):354-66. doi: 10.1208/s12248-012-9436-4. Epub 2012 Dec 19.

Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Curr Drug Targets. 2012 Nov;13(12):1525-34. doi: 10.2174/138945012803530062.

The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.

AAPS J. 2011 Mar;13(1):111-20. doi: 10.1208/s12248-011-9253-1. Epub 2011 Jan 19.

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Target Oncol. 2010 Mar;5(1):65-72. doi: 10.1007/s11523-010-0137-6. Epub 2010 Apr 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.

作者信息

Takimoto Chris H

机构信息

Ortho Biotech Oncology Research & Development, Radnor, PA, USA.

出版信息

Eur J Cancer. 2009 Sep;45 Suppl 1:436-8. doi: 10.1016/S0959-8049(09)70080-2.

DOI:10.1016/S0959-8049(09)70080-2

PMID:19775662

Abstract

摘要

相似文献

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.

Eur J Cancer. 2009 Sep;45 Suppl 1:436-8. doi: 10.1016/S0959-8049(09)70080-2.

Using biomarkers in drug development.

Clin Adv Hematol Oncol. 2006 Oct;4(10):736-9.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. doi: 10.1158/1078-0432.CCR-03-0785.

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18.

Pharmacodynamic biomarkers for molecular cancer therapeutics.

Adv Cancer Res. 2007;96:213-68. doi: 10.1016/S0065-230X(06)96008-4.

Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086.

Biomarkers in early cancer drug development: limited utility.

Clin Pharmacol Ther. 2009 Feb;85(2):134-5. doi: 10.1038/clpt.2008.231.

Ex vivo biomarkers: functional tools to guide targeted drug development and therapy.

Expert Rev Mol Diagn. 2009 Nov;9(8):787-94. doi: 10.1586/erm.09.62.

Promises of biomarkers in drug development--a reality check.

Chem Biol Drug Des. 2007 Jun;69(6):381-94. doi: 10.1111/j.1747-0285.2007.00522.x.

New science-based endpoints to accelerate oncology drug development.

Eur J Cancer. 2005 Mar;41(4):491-501. doi: 10.1016/j.ejca.2004.12.006. Epub 2005 Jan 22.

引用本文的文献

NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA.

bioRxiv. 2024 Dec 25:2024.12.25.630315. doi: 10.1101/2024.12.25.630315.

Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Nat Rev Clin Oncol. 2021 Jul;18(7):454-467. doi: 10.1038/s41571-021-00489-x. Epub 2021 Mar 24.

Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.

Oncotarget. 2017 Jul 18;8(29):48178-48185. doi: 10.18632/oncotarget.18380.

Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

AAPS J. 2013 Apr;15(2):354-66. doi: 10.1208/s12248-012-9436-4. Epub 2012 Dec 19.

Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Curr Drug Targets. 2012 Nov;13(12):1525-34. doi: 10.2174/138945012803530062.

The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.

AAPS J. 2011 Mar;13(1):111-20. doi: 10.1208/s12248-011-9253-1. Epub 2011 Jan 19.

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Target Oncol. 2010 Mar;5(1):65-72. doi: 10.1007/s11523-010-0137-6. Epub 2010 Apr 2.